Free Trial

Avicanna (AVCNF) Stock Price, News & Analysis

+0.01 (+3.10%)
(As of 05/24/2024 08:50 PM ET)
Today's Range
50-Day Range
52-Week Range
13,300 shs
Average Volume
12,345 shs
Market Capitalization
P/E Ratio
Dividend Yield
Price Target
AVCNF stock logo

About Avicanna Stock (OTC:AVCNF)

Avicanna Inc., a commercial-stage biopharmaceutical company, engages in the research and development of evidence-based products for consumer medical and pharmaceutical segments worldwide. The company collaborates with Canadian academic and medical institutions. Its scientific platform includes research and development, and clinical development that leads to the commercialization of approximately twenty products across four main market segments. The company provides medical and wellness products containing cannabidiol, cannabigerol, and tetrahydrocannabinol under the RHO Phyto brand; functional CBD consumer derma-cosmetic and topical products under the Pura H&W and Pura Earth brand names; and cannabis dried flowers, standardized seeds, full spectrum extracts, cannabinoid distillates, isolated cannabinoids, and bulk formulations derived from hemp and cannabis cultivars under the Aureus brand. It also develops pharmaceutical products for epidermolysis bullosa, dermatology, chronic pain, and various neurological disorders. The company has research collaboration with Dr. Christine Allen'sResearch Group for the development of a cannabinoid-based treatment for lung inflammation associated with COVID19. Avicanna Inc. was incorporated in 2016 and is headquartered in Toronto, Canada.

AVCNF Stock Price History

AVCNF Stock News Headlines

Avicanna Hosts Symposium on Cannabinoid-based Medicine
Closing Bell: Avicanna Inc flat on Tuesday (AVCN)
See More Headlines
Receive AVCNF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Avicanna and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Drug Manufacturers - Specialty & Generic
Year Founded


Pretax Margin


Sales & Book Value

Annual Sales


Free Float
Not Optionable
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Mr. Aras Azadian B.Econ
    Mba, Co-Founder, CEO & Director
  • Mr. Phillip Cardella C.A.
    CPA, Chief Financial Officer
  • Dr. Frantz Le Devedec
    Executive Vice President of Research & Development
  • Mr. Stephen Kim
    Chief Legal Officer & General Counsel of Avicanna USA Inc.
  • Mr. Arash Moghani MBA
    Executive Vice President of Operations & Technology
  • Ms. Ingrid Diaz
    VP, Assistant General Counsel & Corporate Compliance Officer
  • Ms. Ivana Maric
    Executive Vice President of Marketing
  • Mr. Enric Pujol
    Vice President of People
  • Dr. Carlos Enrique Maldonado Muete
    SVP of Clinical Development
  • Dr. Karolina Urban
    Executive Vice President of Scientific & Medical Affairs

AVCNF Stock Analysis - Frequently Asked Questions

How have AVCNF shares performed in 2024?

Avicanna's stock was trading at $0.2683 on January 1st, 2024. Since then, AVCNF stock has decreased by 28.1% and is now trading at $0.1929.
View the best growth stocks for 2024 here

How do I buy shares of Avicanna?

Shares of AVCNF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTC:AVCNF) was last updated on 5/28/2024 by Staff

From Our Partners